Detection of isoniazid-, fluoroquinolone-, amikacin-, and kanamycin-resistant tuberculosis in an automated, multiplexed 10-color assay suitable for point-of-care use

Journal of Clinical Microbiology

Volumn 55, Issue 1, 2017, Pages 183-198

  Chakravorty, Soumitesh ^a   Roh, Sandy S ^a   Glass, Jennifer ^b   Smith, Laura E ^a   Simmons, Ann Marie ^b   Lund, Kevin ^c   Lokhov, Sergey ^c   Liu, Xin ^d   Xu, Peng ^e   Zhang, Guolong ^f,g   Via, Laura E ^h,i   Shen, Qingyu ^f   Ruan, Xianglin ^d   Yuan, Xing ^d   Zhu, Hong Zhu ^f   Viazovkina, Ekaterina ^c   Shenai, Shubhada ^a   Rowneki, Mazhgan ^a   Lee, Jong Seok ^j   Barry, Clifton E ^h,i   Gao, Qian ^e   Persing, David ^b   Kwiatkawoski, Robert ^b   Jones, Martin ^b   Gall, Alexander ^c   Alland, David ^a   more..

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b CEPHEID   (United States)

^c Cepheid   (United States)

^d Department of Cardiology   (China)

^e FUDAN UNIVERSITY   (China)

^f Sino US International Research Center of Tuberculosis   (China)

^g Henan Public Health Clinical Center   (China)

^h NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

ⁱ UNIVERSITY OF CAPE TOWN   (South Africa)

^j International Tuberculosis Research Center   (South Korea)

more..

Author keywords

10 color assay; Point of care test; Three phase PCR; XDR TB

Indexed keywords

AMIKACIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE (ATP HYDROLYSING) B; ISONIAZID; KANAMYCIN; KATG PROTEIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; BACTERIAL DNA; QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL MUTATION; BACTERIUM MUTANT; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); COLONY FORMING UNIT; CONTROLLED STUDY; EIS GENE; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; GENE AMPLIFICATION; GYRA GENE; GYRB GENE; HUMAN; INHA GENE; KATG GENE; LABORATORY AUTOMATION; LIMIT OF DETECTION; MELTING POINT; MOLECULAR BEACON; MOLECULAR PROBE; MULTIDRUG RESISTANT TUBERCULOSIS; MULTIPLEX POLYMERASE CHAIN REACTION; NONHUMAN; POINT OF CARE TESTING; POLYMERASE CHAIN REACTION SYSTEM; PRIORITY JOURNAL; PROMOTER REGION; RRS GENE; SANGER SEQUENCING; SENSITIVITY AND SPECIFICITY; SPUTUM CULTURE; WILD TYPE; ALLELE; DRUG EFFECTS; EVALUATION STUDY; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; GENETICS; MICROBIOLOGY; MOLECULAR DIAGNOSIS; MYCOBACTERIUM TUBERCULOSIS; POINT OF CARE SYSTEM; POLYMERASE CHAIN REACTION; PROCEDURES;

ALLELES; AMIKACIN; ANTITUBERCULAR AGENTS; AUTOMATION, LABORATORY; DNA, BACTERIAL; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FLUOROQUINOLONES; GENES, BACTERIAL; HUMANS; ISONIAZID; KANAMYCIN; MOLECULAR DIAGNOSTIC TECHNIQUES; MYCOBACTERIUM TUBERCULOSIS; POINT-OF-CARE SYSTEMS; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

EID: 85008311676     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.01771-16     Document Type: Article

References (57)

1. Bonnet M, Sizaire V, Kebede Y, Janin A, Doshetov D, Mirzoian B, Arzumanian A, Muminov T, Iona E, Rigouts L, Rusch-Gerdes S, Varaine F. 2005. Does one size fit all? Drug resistance and standard treatments: results of six tuberculosis programmes in former Soviet countries. Int J Tuberc Lung Dis 9:1147-1154.
2. Lin J, Sattar AN, Puckree T. 2004. An alarming rate of drug-resistant tuberculosis at Ngwelezane Hospital in northern KwaZulu Natal, South Africa. Int J Tuberc Lung Dis 8:568-573.
3. Liu CE, Chen CH, Hsiao JH, Young TG, Tsay RW, Fung CP. 2004. Drug resistance of Mycobacterium tuberculosis complex in central Taiwan. J Microbiol Immunol Infect 37:295-300.
4. Mokrousov I, Otten T, Vyshnevskiy B, Narvskaya O. 2003. Allele-specific rpoB PCR assays for detection of rifampin-resistant Mycobacterium tuberculosis in sputum smears. Antimicrob Agents Chemother 47: 2231-2235. https://doi.org/10.1128/AAC.47.7.2231-2235.2003.
5. Negi SS, Gupta S, Lal S. 2003. Drug resistance in tuberculosis in Delhi: a 2 year profile (2001-2002). J Commun Dis 35:74-81.
6. Raviglione MC, Smith IM. 2007. XDR tuberculosis - implications for global public health. N Engl J Med 356:656-659. https://doi.org/10.1056/NEJMp068273.
7. Faustini A, Hall AJ, Perucci CA. 2005. Tuberculosis treatment outcomes in Europe: a systematic review. Eur Respir J 26:503-510. https://doi.org/10.1183/09031936.05.00103504.
8. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, Zeller K, Andrews J, Friedland G. 2006. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 368:1575-1580. https://doi.org/10.1016/S0140-6736(06)69573-1.
9. Goble M, Iseman MD, Madsen LA, Waite D, Ackerson L, Horsburgh CR, Jr. 1993. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 328:527-532. https://doi.org/10.1056/NEJM199302253280802.
10. Iseman MD. 1993. Treatment of multidrug-resistant tuberculosis. N Engl J Med 329:784-791. https://doi.org/10.1056/NEJM199309093291108.
11. Iseman MD. 1999. Management of multidrug-resistant tuberculosis. Chemotherapy 45(Suppl 2):S3-S11.
12. Kent PT, Kubica GP. 1985. Public health mycobacteriology: a guide for level III laboratory. Centers for Disease Control, U.S. Department of Health and Human Services, Atlanta, GA.
13. Heifets L, Linder T, Sanchez T, Spencer D, Brennan J. 2000. Two liquid medium systems, mycobacteria growth indicator tube and MB redox tube, for Mycobacterium tuberculosis isolation from sputum specimens. J Clin Microbiol 38:1227-1230.
14. Ajbani K, Shetty A, Mehta A, Rodrigues C. 2011. Rapid diagnosis of extensively drug-resistant tuberculosis by use of a reverse line blot hybridization assay. J Clin Microbiol 49:2546-2551. https://doi.org/10.1128/JCM.02511-10.
15. Balasingham SV, Davidsen T, Szpinda I, Frye SA, Tonjum T. 2009. Molecular diagnostics in tuberculosis: basis and implications for therapy. Mol Diagn Ther 13:137-151. https://doi.org/10.1007/BF03256322.
16. Campbell PJ, Morlock GP, Sikes RD, Dalton TL, Metchock B, Starks AM, Hooks DP, Cowan LS, Plikaytis BB, Posey JE. 2011. Molecular detection of mutations associated with first-and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis. Antimicrob Agents Chemother 55:2032-2041. https://doi.org/10.1128/AAC.01550-10.
17. Dauendorffer JN, Guillemin I, Aubry A, Truffot-Pernot C, Sougakoff W, Jarlier V, Cambau E. 2003. Identification of mycobacterial species by PCR sequencing of quinolone resistance-determining regions of DNA gyrase genes. J Clin Microbiol 41:1311-1315. https://doi.org/10.1128/JCM.41.3.1311-1315.2003.
18. Feng Y, Liu S, Wang Q, Wang L, Tang S, Wang J, Lu W. 2013. Rapid diagnosis of drug resistance to fluoroquinolones, amikacin, capreomycin, kanamycin and ethambutol using genotype MTBDRsl assay: a metaanalysis. PLoS One 8:e55292. https://doi.org/10.1371/journal.pone.0055292.
19. Feuerriegel S, Cox HS, Zarkua N, Karimovich HA, Braker K, Rusch-Gerdes S, Niemann S. 2009. Sequence analyses of just four genes to detect extensively drug-resistant Mycobacterium tuberculosis strains in multidrug-resistant tuberculosis patients undergoing treatment. Antimicrob Agents Chemother 53:3353-3356. https://doi.org/10.1128/AAC.00050-09.
20. Hillery N, Groessl EJ, Trollip A, Catanzaro D, Jackson L, Rodwell TC, Garfein RS, Lin SY, Eisenach K, Ganiats TG, Park D, Valafar F, Rodrigues C, Crudu V, Victor TC, Catanzaro A. 2014. The Global Consortium for Drug-Resistant Tuberculosis Diagnostics (GCDD): design of a multi-site, head-to-head study of three rapid tests to detect extensively drugresistant tuberculosis. Trials 15:434. https://doi.org/10.1186/1745-6215-15-434.
21. Kalokhe AS, Shafiq M, Lee JC, Ray SM, Wang YF, Metchock B, Anderson AM, Nguyen ML. 2013. Multidrug-resistant tuberculosis drug susceptibility and molecular diagnostic testing. Am J Med Sci 345:143-148. https://doi.org/10.1097/MAJ.0b013e31825d32c6.
22. O'Grady J, Maeurer M, Mwaba P, Kapata N, Bates M, Hoelscher M, Zumla A. 2011. New and improved diagnostics for detection of drug-resistant pulmonary tuberculosis. Curr Opin Pulm Med 17:134-141. https://doi.org/10.1097/MCP.0b013e3283452346.
23. Rodwell TC, Valafar F, Douglas J, Qian L, Garfein RS, Chawla A, Torres J, Zadorozhny V, Kim MS, Hoshide M, Catanzaro D, Jackson L, Lin G, Desmond E, Rodrigues C, Eisenach K, Victor TC, Ismail N, Crudu V, Gler MT, Catanzaro A. 2014. Predicting extensively drug-resistant Mycobacterium tuberculosis phenotypes with genetic mutations. J Clin Microbiol 52:781-789. https://doi.org/10.1128/JCM.02701-13.
24. Helb D, Jones M, Story E, Boehme C, Wallace E, Ho K, Kop J, Owens MR, Rodgers R, Banada P, Safi H, Blakemore R, Lan NT, Jones-Lopez EC, Levi M, Burday M, Ayakaka I, Mugerwa RD, McMillan B, Winn-Deen E, Christel L, Dailey P, Perkins MD, Persing DH, Alland D. 2010. Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of ondemand, near-patient technology. J Clin Microbiol 48:229-237. https://doi.org/10.1128/JCM.01463-09.
25. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, Allen J, Tahirli R, Blakemore R, Rustomjee R, Milovic A, Jones M, O'Brien SM, Persing DH, Ruesch-Gerdes S, Gotuzzo E, Rodrigues C, Alland D, Perkins MD. 2010. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 363:1005-1015. https://doi.org/10.1056/NEJMoa0907847.
26. Boehme CC, Nicol MP, Nabeta P, Michael JS, Gotuzzo E, Tahirli R, Gler MT, Blakemore R, Worodria W, Gray C, Huang L, Caceres T, Mehdiyev R, Raymond L, Whitelaw A, Sagadevan K, Alexander H, Albert H, Cobelens F, Cox H, Alland D, Perkins MD. 2011. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 377:1495-1505. https://doi.org/10.1016/S0140-6736(11)60438-8.
27. Steingart KR, Schiller I, Horne DJ, Pai M, Boehme CC, Dendukuri N. 2014. Xpert(R) MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev 1:CD009593. https://doi.org/10.1002/14651858.CD009593.pub3.
28. Hazbon MH, Brimacombe M, Bobadilla del Valle M, Cavatore M, Guerrero MI, Varma-Basil M, Billman-Jacobe H, Lavender C, Fyfe J, Garcia-Garcia L, Leon CI, Bose M, Chaves F, Murray M, Eisenach KD, Sifuentes-Osornio J, Cave MD, Ponce de Leon A, Alland D. 2006. Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 50:2640-2649. https://doi.org/10.1128/AAC.00112-06.
29. Cui Z, Wang J, Lu J, Huang X, Hu Z. 2011. Association of mutation patterns in gyrA/B genes and ofloxacin resistance levels in Mycobacterium tuberculosis isolates from East China in 2009. BMC Infect Dis 11:78. https://doi.org/10.1186/1471-2334-11-78.
30. Shi R, Zhang J, Li C, Kazumi Y, Sugawara I. 2006. Emergence of ofloxacin resistance in Mycobacterium tuberculosis clinical isolates from China as determined by gyrA mutation analysis using denaturing high-pressure liquid chromatography and DNA sequencing. J Clin Microbiol 44: 4566-4568. https://doi.org/10.1128/JCM.01916-06.
31. Singh P, Jain A, Dixit P, Prakash S, Jaiswal I, Venkatesh V, Singh M. 2014. Prevalence of gyrA and B gene mutations in fluoroquinolone-resistant and-sensitive clinical isolates of Mycobacterium tuberculosis and their relationship with MIC of ofloxacin. J Antibiot (Tokyo) 68:63-66. https://doi.org/10.1038/ja.2014.95.
32. Wang JY, Lee LN, Lai HC, Wang SK, Jan IS, Yu CJ, Hsueh PR, Yang PC. 2007. Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure. J Antimicrob Chemother 59:860-865. https://doi.org/10.1093/jac/dkm061.
33. Zhang H, Li D, Zhao L, Fleming J, Lin N, Wang T, Liu Z, Li C, Galwey N, Deng J, Zhou Y, Zhu Y, Gao Y, Wang S, Huang Y, Wang M, Zhong Q, Zhou L, Chen T, Zhou J, Yang R, Zhu G, Hang H, Zhang J, Li F, Wan K, Wang J, Zhang XE, Bi L. 2013. Genome sequencing of 161 Mycobacterium tuberculosis isolates from China identifies genes and intergenic regions associated with drug resistance. Nat Genet 45:1255-1260. https://doi.org/10.1038/ng.2735.
34. Chakravorty S, Lee JS, Cho EJ, Roh SS, Smith LE, Lee J, Kim CT, Via LE, Cho SN, Barry CE, III, Alland D. 2015. Genotypic susceptibility testing of Mycobacterium tuberculosis for amikacin and kanamycin resistance using a rapid sloppy molecular beacon-based assay identifies more cases of low-level drug resistance than phenotypic Lowenstein-Jensen testing. J Clin Microbiol 53:43-51. https://doi.org/10.1128/JCM.02059-14.
35. Georghiou SB, Magana M, Garfein RS, Catanzaro DG, Catanzaro A, Rodwell TC. 2012. Evaluation of genetic mutations associated with Mycobacterium tuberculosis resistance to amikacin, kanamycin and capreomycin: a systematic review. PLoS One 7:e33275. https://doi.org/10.1371/journal.pone.0033275.
36. Maus CE, Plikaytis BB, Shinnick TM. 2005. Molecular analysis of crossresistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother 49:3192-3197. https://doi.org/10.1128/AAC.49.8.3192-3197.2005.
37. Luo T, Jiang L, Sun W, Fu G, Mei J, Gao Q. 2011. Multiplex real-time PCR melting curve assay to detect drug-resistant mutations of Mycobacterium tuberculosis. J Clin Microbiol 49:3132-3138. https://doi.org/10.1128/JCM.02046-10.
38. Morgan M, Kalantri S, Flores L, Pai M. 2005. A commercial line probe assay for the rapid detection of rifampicin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. BMC Infect Dis 5:62. https://doi.org/10.1186/1471-2334-5-62.
39. Rossau R, Traore H, De Beenhouwer H, Mijs W, Jannes G, De Rijk P, Portaels F. 1997. Evaluation of the INNO-LiPA Rif. TB assay, a reverse hybridization assay for the simultaneous detection of Mycobacterium tuberculosis complex and its resistance to rifampin. Antimicrob Agents Chemother 41:2093-2098.
40. Albert H, Bwanga F, Mukkada S, Nyesiga B, Ademun JP, Lukyamuzi G, Haile M, Hoffner S, Joloba M, O'Brien R. 2010. Rapid screening of MDR-TB using molecular line probe assay is feasible in Uganda. BMC Infect Dis 10:41. https://doi.org/10.1186/1471-2334-10-41.
41. Ling DI, Zwerling AA, Pai M. 2008. GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis. Eur Respir J 32:1165-1174. https://doi.org/10.1183/09031936.00061808.
42. Chakravorty S, Aladegbami B, Thoms K, Lee JS, Lee EG, Rajan V, Cho EJ, Kim H, Kwak H, Kurepina N, Cho SN, Kreiswirth B, Via LE, Barry CE, III, Alland D. 2011. Rapid detection of fluoroquinolone-resistant and heteroresistant Mycobacterium tuberculosis by use of sloppy molecular beacons and dual melting-temperature codes in a real-time PCR assay. J Clin Microbiol 49:932-940. https://doi.org/10.1128/JCM.02271-10.
43. Gyllensten UB, Erlich HA. 1988. Generation of single-stranded DNA by the polymerase chain reaction and its application to direct sequencing of the HLA-DQA locus. Proc Natl Acad Sci U S A 85:7652-7656. https://doi.org/10.1073/pnas.85.20.7652.
44. Chen J, Chen Z, Li Y, Xia W, Chen X, Chen T, Zhou L, Xu B, Xu S. 2012. Characterization of gyrA and gyrB mutations and fluoroquinolone resistance in Mycobacterium tuberculosis clinical isolates from Hubei Province, China. Braz J Infect Dis 16:136-141. https://doi.org/10.1016/S1413-8670(12)70294-5.
45. Huyen MN, Cobelens FG, Buu TN, Lan NT, Dung NH, Kremer K, Tiemersma EW, van Soolingen D. 2013. Epidemiology of isoniazid resistance mutations and their effect on tuberculosis treatment outcomes. Antimicrob Agents Chemother 57:3620-3627. https://doi.org/10.1128/AAC.00077-13.
46. Sirgel FA, Warren RM, Streicher EM, Victor TC, van Helden PD, Bottger EC. 2012. gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis. J Antimicrob Chemother 67:1088-1093. https://doi.org/10.1093/jac/dks033.
47. Hofmann-Thiel S, van Ingen J, Feldmann K, Turaev L, Uzakova GT, Murmusaeva G, van Soolingen D, Hoffmann H. 2009. Mechanisms of heteroresistance to isoniazid and rifampin of Mycobacterium tuberculosis in Tashkent, Uzbekistan. Eur Respir J 33:368-374. https://doi.org/10.1183/09031936.00089808.
48. Mekonnen D, Admassu A, Mulu W, Amor A, Benito A, Gelaye W, Biadglegne F, Abera B. 2015. Multidrug-resistant and heteroresistant Mycobacterium tuberculosis and associated gene mutations in Ethiopia. Int J Infect Dis 39:34-38. https://doi.org/10.1016/j.ijid.2015.06.013.
49. Pholwat S, Stroup S, Foongladda S, Houpt E. 2013. Digital PCR to detect and quantify heteroresistance in drug resistant Mycobacterium tuberculosis. PLoS One 8:e57238. https://doi.org/10.1371/journal.pone.0057238.
50. Tolani MP, D'Souza DT, Mistry NF. 2012. Drug resistance mutations and heteroresistance detected using the GenoType MTBDRplus assay and their implication for treatment outcomes in patients from Mumbai, India. BMC Infect Dis 12:9. https://doi.org/10.1186/1471-2334-12-9.
51. Cox HS, Mbhele S, Mohess N, Whitelaw A, Muller O, Zemanay W, Little F, Azevedo V, Simpson J, Boehme CC, Nicol MP. 2014. Impact of Xpert MTB/RIF for TB diagnosis in a primary care clinic with high TB and HIV prevalence in South Africa: a pragmatic randomised trial. PLoS Med 11:e1001760. https://doi.org/10.1371/journal.pmed.1001760.
52. Alonso M, Palacios JJ, Herranz M, Penedo A, Menendez A, Bouza E, Garcia de Viedma D. 2011. Isolation of Mycobacterium tuberculosis strains with a silent mutation in rpoB leading to potential misassignment of resistance category. J Clin Microbiol 49:2688-2690. https://doi.org/10.1128/JCM.00659-11.
53. Chakravorty S, Aladegbami B, Burday M, Levi M, Marras SA, Shah D, El-Hajj HH, Kramer FR, Alland D. 2010. Rapid universal identification of bacterial pathogens from clinical cultures by using a novel sloppy molecular beacon melting temperature signature technique. J Clin Microbiol 48:258-267. https://doi.org/10.1128/JCM.01725-09.
54. Chakravorty S, Kothari H, Aladegbami B, Cho EJ, Lee JS, Roh SS, Kim H, Kwak H, Lee EG, Hwang SH, Banada PP, Safi H, Via LE, Cho SN, Barry CE, III, Alland D. 2012. Rapid, high-throughput detection of rifampin resistance and heteroresistance in Mycobacterium tuberculosis by use of sloppy molecular beacon melting temperature coding. J Clin Microbiol 50:2194-2202. https://doi.org/10.1128/JCM.00143-12.
55. Sambandamurthy VK, Wang X, Chen B, Russell RG, Derrick S, Collins FM, Morris SL, Jacobs WR, Jr. 2002. A pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated and protects mice against tuberculosis. Nat Med 8:1171-1174. https://doi.org/10.1038/nm765.
56. Lee J, Armstrong DT, Ssengooba W, Park JA, Yu Y, Mumbowa F, Namaganda C, Mboowa G, Nakayita G, Armakovitch S, Chien G, Cho SN, Via LE, Barry CE, III, Ellner JJ, Alland D, Dorman SE, Joloba ML. 2014. Sensititre MYCOTB MIC plate for testing Mycobacterium tuberculosis susceptibility to first-and second-line drugs. Antimicrob Agents Chemother 58:11-18. https://doi.org/10.1128/AAC.01209-13.
57. Song T, Park Y, Shamputa IC, Seo S, Lee SY, Jeon HS, Choi H, Lee M, Glynne RJ, Barnes SW, Walker JR, Batalov S, Yusim K, Feng S, Tung CS, Theiler J, Via LE, Boshoff HI, Murakami KS, Korber B, Barry CE, III, Cho SN. 2014. Fitness costs of rifampicin resistance in Mycobacterium tuberculosis are amplified under conditions of nutrient starvation and compensated by mutation in the subunit of RNA polymerase. Mol Microbiol 91:1106-1119. https://doi.org/10.1111/mmi.12520.